Patent application number | Description | Published |
20080267941 | Nutrition Comprising Betaine Against Muscle Wasting - The invention relates to the treatment or the reduction of the incidence of muscle wasting in humans and to a complete nutritional composition patients suffering from muscle wasting comprising betaine and preferably coenzyme Q10. | 10-30-2008 |
20080269117 | Preparation for Use of Aspartate for Regulating Glucose Levels in Blood - The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1. | 10-30-2008 |
20080275120 | LEUCINE RICH COMPOSITION - The invention relates to the use of a composition comprising proteinaceous matter, said providing at least 24.0% of the energetic value of the composition (en %) and at least 12 wt. % based on proteinaceous matter leucine in the manufacture of a medicament for the treatment of insulin resistance and to a composition suitable for administration to a mammal comprising a protein fraction, a carbohydrate fraction and a lipid fraction, wherein the protein fraction provides at least 24.0 % (en %), the carbohydrate provides up to 46 en %, the lipid fraction provides up to 30 en % and wherein at least 12 wt. %, based on proteinaceous matter, of leucine. | 11-06-2008 |
20080292724 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:
| 11-27-2008 |
20080317868 | COMPOSITION FOR IMPROVING MEMBRANE COMPOSITION AND FUNCTIONING CELLS - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:
| 12-25-2008 |
20090081179 | METHOD FOR REDUCING THE SEVERITY OF NEUROLOGICAL DISORDERS - The present invention relates to the use of
| 03-26-2009 |
20090104283 | METHOD FOR REDUCING THE SEVERITY OF NEUROLOGICAL DISORDERS - The present invention relates to the use of
| 04-23-2009 |
20090181154 | NON-ALLERGENIC INGREDIENTS AND FOOD PRODUCTS - The present invention relates to a non-allergenic food product, comprising an amino acid fraction comprising at least one component selected from the group consisting of amino acids and peptides having a degree of polymerization of 7 or less; and a lipid fraction comprising at least one fatty acid selected from the group consisting of arachidonic acid and docosahexanoic acid, the composition having a content of proteins and other peptides having a molecular weight of 1000 dalton or more of less than 0.01 wt. %, based on the dry weight, preferably less than 0.001 wt. %, more preferably less than 0.0001 wt %. | 07-16-2009 |
20090203573 | USE OF DIETARY FIBRES AGAINST MUSCLE WASTING - A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units. | 08-13-2009 |
20100069327 | NUTRITIONAL PRODUCTS COMPRISING SACCHARIDE OLIGOMERS - Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal. | 03-18-2010 |
20100129461 | Process for Dispersing Amino Acids - A coated proteinaceous material can be produced by contacting the proteinaceous material with de-oiled phospholipids or mixtures thereof containing less than 20% triglycerides. The coating has between 0.1 and 1.5% by weight of the total proteinaceous material, of de-oiled lecithin. The proteinaceous material is hydrophobic, especially amino acids having a hydrophobicity of higher than 1.0 kJ/mol. In particular, the amino acids are leucine, isoleucine, valine, phenylalanine, tryptophan and/or methionine. The coated amino acids can be incorporated into food product and medicaments. | 05-27-2010 |
20100159109 | DEVICE AND A METHOD FOR PREPARING A READY TO USE LIQUID PRODUCT - The invention relates to a device | 06-24-2010 |
20100236966 | CONTAINER ASSEMBLY HAVING STACKING MEANS - Container assembly includes a container part and a lid part. The lid part has a connection portion to be connected to the container part. For automatic assembly of the container assembly from the container part and the lid part it is advantageous that separate lid parts can be manipulated easily. To that end it is proposed to embody the lid parts such a way that they are stackable in a stable way. More particular it is proposed to provide the top side of the lid with a circumferential cam which can engage inside a circumferential rim of the connection portion. To be able to remove dust and debris from the top side of the lid it is proposed to provide a circumferential cam with interruptions. When part of the lid is shaped to correspond with part of the spoon, the interruption should preferably located at such shape such as a spoon. | 09-23-2010 |
20100260777 | TREATMENT AND/OR PREVENTION OF SEPSIS USING AN ENTERAL COMPOSITION - Treatment and/or prevention of sepsis using an enteral composition containing phospholipids, triglycerides and cholesterol or precursors thereof. With the composition of the invention the natural level of chylomicrons is maintained, in particular in gut associated lymphoid tissue (GALT), which ensures that most of LPS and/or LTA which are released in the body can be neutralized, substantially decreasing the risk of locally occurring high levels of LPS and/or LTA and thus sepsis. | 10-14-2010 |
20100261669 | UNIT DOSAGE FOR BRAIN HEALTH - The invention pertains to a composition comprising (i) uridine in nucleobase, nucleoside and/or nucleotide form; (ii) docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA); and (iii) a tocopherol and/or an equivalent thereof, wherein said composition has: a) a weight of 200-3000 mg per unit dose; b) an energy content of less than 50 kcal per unit dose; and/or c) a volume between 0.1 and 10 ml per unit dose. The invention also pertains to the use of such composition in reducing abeta plaque burden and neurodegeneration, in the treatment of diseases related with imparted nerve functioning, in particular dementia, Alzheimer's disease and memory disorders. | 10-14-2010 |
20100323982 | FOOD COMPOSITION FOR PRODROMAL DEMENTIA PATIENTS - A composition comprising (a) one or more ω-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350 ng Total-tau per litre cerebrospinal fluid (CSF), and a weight ratio of abeta-42/Phospho-tau-181 of less than 6.5 in CSF. | 12-23-2010 |
20100331275 | SUPPORTING ACTIVITIES OF DAILY LIVING - The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping. | 12-30-2010 |
20110009357 | LIPID COMPOSITION FOR IMPROVING BRAIN FUNCTION - The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g α-linolenic acid per 100 g fatty acids of the lipid fraction. | 01-13-2011 |
20110027391 | LIQUID NUCLEOTIDES/NUCLEOSIDES-CONTAINING PRODUCT - The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of 5 thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan δ between 0.1 and 100, as measured at any strain in the range of 1 100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation. | 02-03-2011 |
20110150824 | Nutritional Composition for Improving the Mammalian Immune System - The invention relates to a nutritional composition comprising
| 06-23-2011 |
20110152184 | Nutritional Composition for Improving Muscle Function and Daily Activity - The invention relates to a nutritional composition comprising | 06-23-2011 |
20110288016 | PREPARATION FOR USE OF ASPARTATE AND VITAMIN B12 OR BIOTIN FOR REGULATING KETONE BODIES - It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents. | 11-24-2011 |
20120058938 | NUTRITIONAL COMPOSITION INDUCING A POSTPRANDIAL ENDOCRINE RESPONSE - The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction. | 03-08-2012 |
20120122785 | COMBINATION OF A LEUCINE SOURCE AND AN OMEGA- 3 UNSATURATED FATTY ACID SOURCE FOR USE IN THE TREATMENT OF HYPERCALCAEMIA - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 05-17-2012 |
20120165243 | USE OF DIETARY FIBRES AGAINST MUSCLE WASTING - A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units. | 06-28-2012 |
20130012469 | LIQUID NUCLEOTIDES/NUCLEOSIDES-CONTAINING PRODUCT - The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan δ between 0.1 and 100, as measured at any strain in the range of 1-100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation. | 01-10-2013 |
20130018012 | LIPID COMPOSITION FOR IMPROVING BRAIN FUNCTION - The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g α-linolenic acid per 100 g fatty acids of the lipid fraction. | 01-17-2013 |
20130219987 | Novel Glucose Tolerance Test and Composition for Use - The present invention relates to a liquid nutritional composition, to a liquid nutritional composition for use in a diagnostic method for screening of a glucose-intolerant condition, to a kit for screening of a glucose-intolerant condition, and to a diagnostic method for screening a mammal for a glucose-intolerant condition. Furthermore, it refers to a liquid nutritional composition for use as a standard reference nutrition, such as for classification of postprandial glucose responses of different nutritional compositions. The liquid nutritional composition comprises protein, fat, digestible carbohydrate and dietary fibre, wherein the digestible carbohydrate comprises at least 90 weight % of glucose units, based on total digestible carbohydrate mass and preferably is substantially free of fructose. | 08-29-2013 |
20130295146 | Composition for Improving Membrane Composition and Functioning of Cells - It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises:
| 11-07-2013 |
20130330424 | Non-Medical Increase or Maintenance of Body Weight of a Mammal - Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal. | 12-12-2013 |
20130331352 | Combination of Components for the Prevention and Treatment of Frailty - Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction. | 12-12-2013 |
20140066397 | METHOD FOR TREATING NEUROTRAUMA - The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of □-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury. | 03-06-2014 |
20140099344 | PROCESS FOR DISPERSING AMINO ACIDS - A coated proteinaceous material can be produced by contacting the proteinaceous material with de-oiled phospholipids or mixtures thereof containing less than 20% triglycerides. The coating has between 0.1 and 1.5% by weight of the total proteinaceous material, of de-oiled lecithin. The proteinaceous material is hydrophobic, especially amino acids having a hydrophobicity of higher than 1.0 kJ/mol. In particular, the amino acids are leucine, isoleucine, valine, phenylalanine, tryptophan and/or methionine. The coated amino acids can be incorporated into food products and medicaments. | 04-10-2014 |
20140099416 | DEVICE AND A METHOD FOR PREPARING A READY TO USE LIQUID PRODUCT - A device for preparing a ready-to-use liquid product from a semi-finished product where the semi-finished product is arranged in a first container, the device having an injector for supplying an amount of liquid into the first container for providing the ready-to-use liquid product, and the injector configured to evacuate the ready-to-use liquid product from the first container into a second container. | 04-10-2014 |
20140161928 | Preparation for Use of Aspartate for Regulating Glucose Levels in Blood - The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1. | 06-12-2014 |
20150018277 | Combination of a Leucine Source and an Omega-3 Unsaturated Fatty Acid Source for Use in the Treatment of Hypercalcaemia - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 01-15-2015 |
20150037309 | PREPARATION FOR IMPROVING THE ACTION OF RECEPTORS - The present invention relates to the use of
| 02-05-2015 |